[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650384":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":24,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":34,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":41,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":10},{"fullName":5,"class":6},"Dartmouth-Hitchcock Medical Center","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"PMR diagnosed",null,"individuals who have a PMR diagnosis",{"label":13,"type":10,"description":14,"interventionNames":10},"Healthy Volunteers","Healthy individuals, without a PMR diagnosis, which will allow age and sex matches with the PMR diagnosed cohort.",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Vivekanand Tiwai, MD","CONTACT","(603) 650-8622","vivekanand.tiwari@hitchcock.org",{"name":22,"role":18,"phone":19,"phoneExt":10,"email":23},"Olivia Brooker, BS","olivia.f.brooker@hitchcock.org",{"type":25,"investigatorFullName":26,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Vivekanand.Tiwari","Assistant Professor of Medicine, Staff Rheumatologist","100650384","dna-methylation-in-pmr-100650384",false,"NCT07748195","DNA Methylation in PMR","Inclusion Criteria:\n\nAnyone ≥50-89 years old Taking ≥10mg of prednisone or prednisone equivalent at time of enrollment with a stable disease normal ESR and CRP (inflammation markers) which would indicate presence of inflammation or not\n\n* CRP: \\\u003C1.0 mg\u002FdL (some labs report in mg\u002FL → normal is usually \\\u003C3 mg\u002FL)\n* ESR:\n* Men ≥50 years: 0-20 mm\u002Fhr\n* Women ≥50 years: 0-30 mm\u002Fhr Have a PMR diagnosis Able to provide written consent\n\nExclusion Criteria:\n\n* History of concomitant Giant cell arteritis (GCA) any other rheumatological disorders like lupus, arthritis (psoriatic, osteo), scleroderma, sjogrens Active malignancy- presence of tumor by imaging or labs Infection- infection can cause increased levels of innate immune cells making it difficult to differentiate between disease and infection recent surgery- within the past 6 months",true,"ALL","50 Years","89 Years",{"count":39,"type":40},50,"ESTIMATED","4 Weeks","OBSERVATIONAL","Polymyalgia Rheumatica (PMR) is treated with corticosteroids; however, long-term treatment is not feasible due to side effects. Withdrawal of corticosteroids causes a subset of patients to relapse, and there is no current way to understand what underlies this. Our research team has preliminary data from a small clinical study that indicates that different immune effector dynamics during the tapering of steroids correlate with relapse. This was achieved using the DNA methylation-specific immune cell profiling methods that Dr. Christensen has pioneered. What is proposed is a larger prospective study of 50 PMR patients to validate differences in CD4 and CD8 memory cells as a predictor of relapse. Finally, we also focus on the Glucocorticoid Methylation Index (GCMI), which is a collection of 28 CpG islands that are methylated in response to corticosteroids. This will allow our team to determine the predictive power of the GCMI for PMR.",[45],"Polymyalgia Rheumatica (PMR)","NOT_YET_RECRUITING","2026-08-10",{"date":49,"type":50},"2026-08-12","ACTUAL",{"date":52,"type":40},"2026-07-20",{"date":54,"type":40},"2027-04-01",{"name":5,"class":6}]